This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Halozyme (HALO) Q4 Earnings Top, Royalties Drive Revenues
by Zacks Equity Research
Halozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022.
Prothena (PRTA) Q4 Earnings Beat, Pipeline Progress in Focus
by Zacks Equity Research
Prothena beats on earnings and revenues in the fourth quarter of 2021. The company's progress with its AD pipeline is encouraging.
Top Analyst Reports for Adobe, Altria Group & Marriott International
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), Altria Group, Inc. (MO), and Marriott International, Inc. (MAR).
Blueprint Medicines (BPMC) Q4 Loss Widens, Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.
Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate
by Zacks Equity Research
Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's arthritis drug, Cimzia.
Amgen's (AMGN) Q4 Earnings Top Estimates, Product Sales Fall
by Zacks Equity Research
Amgen (AMGN) beats Q4 estimates for earnings but misses the same for sales. Higher Other Revenue for manufacturing Eli Lilly's COVID-19 antibody boost sales growth.
Regeneron (REGN) Beats on Q4 Earnings, Gains on REGEN-COV
by Zacks Equity Research
Regeneron (REGN) Q4 earnings beat estimates and sales record strong year-over-year growth on the solid performance of REGEN-COV as well as Eylea and Dupixent.
Biogen (BIIB) Q4 Earnings Top, Stock Down on Weak 2022 View
by Zacks Equity Research
Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The stock declines on weak sales and earnings guidance for 2022.
Roche's (RHHBY) 2021 Earnings, Sales Grow on COVID-19 Tests
by Zacks Equity Research
Roche (RHHBY) performance in the fourth quarter and 2021 was encouraging, driven by demand for COVID-19 tests and recovery in pharma sales. However, sales are expected to slow down in 2022.
Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing
by Zacks Equity Research
Novartis (NVS) reports dismal results for the fourth quarter. Key brands maintain momentum but the generics business remains weak.
All You Need to Know About Roche Holding AG (RHHBY) Rating Upgrade to Strong Buy
by Zacks Equity Research
Roche Holding AG (RHHBY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pfizer (PFE) Lorviqua Gets EU Nod for First-Line Lung Cancer
by Zacks Equity Research
The European Commission approves label expansion of Pfizer's (PFE) Lorviqua as a first-line treatment for ALK-positive non-small cell lung cancer.
Is a Beat Likely for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports fourth-quarter results.
AbbVie's (ABBV) Q4 Earnings May Reflect Slower Sales Recovery
by Zacks Equity Research
AbbVie's (ABBV) drugs are expected to have continued the recovering trend in sales during the fourth quarter. However, increased COVID-19 cases are likely to have hurt the pace of recovery during the quarter.
ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC
by Zacks Equity Research
The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.
Biogen (BIIB) to Sell Biosimilar JV Stake to Samsung Biologics
by Zacks Equity Research
Biogen (BIIB) is selling its equity stake in the Samsung Bioepis joint venture to partner Samsung Biologics
Is a Beat Likely for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie's (ABBV) fourth-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics. Investors are likely to focus on any update related to the guidance for 2022.
Pharma Stock Roundup: J&J Q4 Earnings, FDA's Rejection of PFE, MRK Pipeline Drugs
by Kinjel Shah
J&J (JNJ) reports mixed fourth-quarter results. FDA issues CRL to Merck (MRK) and Pfizer's (PFE) pipeline candidates. FDA approves AbbVie's (ABBV) Skyrizi for a second indication.
Karyopharm's (KPTI) Eltanexor Gets Orphan Drug Tag for MDS
by Zacks Equity Research
The FDA bestows an Orphan Drug status to Karyopharm's (KPTI) investigational candidate, eltanexor, for treating myelodysplastic syndromes.
The Zacks Analyst Blog Highlights: Roche Holding, Pfizer, Baxter International, STMicro and Philips
by Zacks Equity Research
Roche Holding, Pfizer, Baxter International, STMicro and Philips are included in this analyst blog.
Here's Why Roche Holding AG (RHHBY) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Roche Holding AG (RHHBY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Oxygen from Earnings: Global Week Ahead
by John Blank
In the Global Week Ahead, Q4 S&P500 earnings will supply the latest details on how major global companies are dealing with rising wage cost pressures.
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis
by Zacks Equity Research
AbbVie (ABBV) secures approval in the United States for Skyrizi to treat adult patients with active psoriatic arthritis.
Regeneron (REGN) Rides on Solid Product Portfolio: Should You Buy?
by Zacks Equity Research
Regeneron (REGN) is expected to maintain momentum on the back of a solid and diverse portfolio. The promising pipeline also sets the stage for further growth.
The Zacks Analyst Blog Highlights: Roche Holding AG, Anthem, Inc. and Infosys Limited
by Zacks Equity Research
Roche Holding AG, Anthem, Inc. and Infosys Limited are highlighted ikn this Analyst Blog article.